Prosecution Insights
Last updated: August 15, 2026

Queen Mary University Of London

6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days

Portfolio Summary

6
Total Pending OAs
3
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due ≤ 30 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

4
Hard (67%)
1
Medium (17%)
1
Easy (17%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 only1 (17%)
§103 only1 (17%)
§112 only1 (17%)
Multi-statute (no §101)3 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
67% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
2
Business / Other
33% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HUANG, DAVID Z 1 80.3% +13.3%
FAUST, AMBER KATHLEEN 1 60.9% +52.1%
AEDER, SEAN E 1 56.9% +19.9%
MCCOLLUM, ANDREA K 1 60.9% +32.2%
LIU, TRACY 1 54.5% +27.3%
NGUYEN, QUANG 1 38.1% +53.0%

Hard Cases (4)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18344502 ROR2 INHIBITORS AND USE THEREOF IN TREATING AND/OR PREVENTING CARTILAGE LOSS MCCOLLUM, ANDREA K 73d overdue
18365369 Method for Determining Prognosis of Cancer AEDER, SEAN E 3d overdue
18850223 FORCE SENSOR HUANG, DAVID Z
18570043 Treatment of Inflammatory Conditions or Diseases FAUST, AMBER KATHLEEN

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
18344502 ROR2 INHIBITORS AND USE THEREOF IN TREATING AND/OR PREVENTING CARTILAGE LOSS MCCOLLUM, ANDREA K 73d overdue
18268933 Composition Comprising Calcium Orthophosphate and a Bioactive Glass Comprising Fluorine LIU, TRACY 38d overdue
18365369 Method for Determining Prognosis of Cancer AEDER, SEAN E 3d overdue
18156184 Oncolytic Vaccinia Virus NGUYEN, QUANG 20d
18850223 FORCE SENSOR HUANG, DAVID Z
18570043 Treatment of Inflammatory Conditions or Diseases FAUST, AMBER KATHLEEN

Top Art Units

Art UnitApps
1642 1
1674 1
1614 1
1631 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18850223 FORCE SENSOR HUANG, DAVID Z §103§112 Non-Final OA Pending Sep 24, 2024
18570043 Treatment of Inflammatory Conditions or Diseases FAUST, AMBER KATHLEEN §102§103§112 Non-Final OA Pending Dec 13, 2023
18365369 Method for Determining Prognosis of Cancer AEDER, SEAN E 1642 §101 Non-Final OA 3d overdue Pending Aug 04, 2023
18344502 ROR2 INHIBITORS AND USE THEREOF IN TREATING AND/OR PREVENTING CARTILAGE LOSS MCCOLLUM, ANDREA K 1674 §102§112 Final Rejection 73d overdue Pending Jun 29, 2023
18268933 Composition Comprising Calcium Orthophosphate and a Bioactive Glass Comprising Fluorine LIU, TRACY 1614 §103 Final Rejection 38d overdue Pending Jun 21, 2023
18156184 Oncolytic Vaccinia Virus NGUYEN, QUANG 1631 §112 Final Rejection 20d Pending Jan 18, 2023

Managing Queen Mary University Of London's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month